Promising New Cancer Drugs Won’t Go Far Unless Everyone Gets Genetic Testing
by from MIT Technology Review on (#2RZZX)
Loxo Oncology is developing a so-called "tumor agnostic" drug that requires expensive genetic testing often not covered by insurance.